These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 16778094)

  • 1. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.
    Kelloff GJ; Lippman SM; Dannenberg AJ; Sigman CC; Pearce HL; Reid BJ; Szabo E; Jordan VC; Spitz MR; Mills GB; Papadimitrakopoulou VA; Lotan R; Aggarwal BB; Bresalier RS; Kim J; Arun B; Lu KH; Thomas ME; Rhodes HE; Brewer MA; Follen M; Shin DM; Parnes HL; Siegfried JM; Evans AA; Blot WJ; Chow WH; Blount PL; Maley CC; Wang KK; Lam S; Lee JJ; Dubinett SM; Engstrom PF; Meyskens FL; O'Shaughnessy J; Hawk ET; Levin B; Nelson WG; Hong WK;
    Clin Cancer Res; 2006 Jun; 12(12):3661-97. PubMed ID: 16778094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
    Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
    Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogate end-point biomarkers in chemopreventive drug development.
    Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
    IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New science-based endpoints to accelerate oncology drug development.
    Kelloff GJ; Sigman CC
    Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer chemoprevention and cancer preventive vaccines--a call to action: leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgent need.
    Herberman RB; Pearce HL; Lippman SM; Pyenson BS; Alberts DS
    Cancer Res; 2006 Dec; 66(24):11540-9. PubMed ID: 17158189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Terpenoids and breast cancer chemoprevention.
    Rabi T; Bishayee A
    Breast Cancer Res Treat; 2009 May; 115(2):223-39. PubMed ID: 18636327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Properties of intraepithelial neoplasia relevant to the development of cancer chemopreventive agents.
    Boone CW; Bacus JW; Bacus JV; Steele VE; Kelloff GJ
    J Cell Biochem Suppl; 1997; 28-29():1-20. PubMed ID: 9589346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarker end-points in cancer chemoprevention trials.
    Boone CW; Kelloff GJ
    IARC Sci Publ; 1997; (142):273-80. PubMed ID: 9354926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Karyometry in the early detection and chemoprevention of intraepithelial lesions.
    Ranger-Moore J; Alberts DS; Montironi R; Garcia F; Davis J; Frank D; Brewer M; Mariuzzi GM; Bartels HG; Bartels PH
    Eur J Cancer; 2005 Sep; 41(13):1875-88. PubMed ID: 16087328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemoprevention of colorectal cancer.
    Das D; Arber N; Jankowski JA
    Digestion; 2007; 76(1):51-67. PubMed ID: 17947819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers and surrogacy: relevance to chemoprevention.
    Kensler TW; Davidson NE; Groopman JD; Muñoz A
    IARC Sci Publ; 2001; 154():27-47. PubMed ID: 11220666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The convergent development of molecular-targeted drugs for cancer treatment and prevention.
    Lippman SM; Heymach JV
    Clin Cancer Res; 2007 Jul; 13(14):4035-41. PubMed ID: 17634526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point.
    Arber N
    Cancer Epidemiol Biomarkers Prev; 2008 Aug; 17(8):1852-7. PubMed ID: 18708371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers.
    Lee JW; Figeys D; Vasilescu J
    Adv Cancer Res; 2007; 96():269-98. PubMed ID: 17161683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cancer prevention].
    Akaza H; Tsuruo T; Saijo N; Sone S; Isonishi S; Ohashi Y; Noguchi S; Kurebayashi J; Kakehi Y; Ishikawa H; Blackledge G
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1499-506. PubMed ID: 16227757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral cancer prevention and the evolution of molecular-targeted drug development.
    Lippman SM; Sudbø J; Hong WK
    J Clin Oncol; 2005 Jan; 23(2):346-56. PubMed ID: 15637397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular markers and targets for colorectal cancer prevention.
    Janakiram NB; Rao CV
    Acta Pharmacol Sin; 2008 Jan; 29(1):1-20. PubMed ID: 18158862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of cancer chemopreventive drugs based on mechanistic approaches.
    Steele VE; Kelloff GJ
    Mutat Res; 2005 Dec; 591(1-2):16-23. PubMed ID: 16083917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.